M. Ghandi

RPL22 is a tumor suppressor in MSI-high cancers and a key splicing regulator of MDM4

This study identifies RPL22 as a tumor suppressor in MSI-H cancers that regulates MDM4 splicing and reveals its role in oncogenic pathways.

Integrated evaluation of telomerase activation and telomere maintenance across cancer cell lines

The paper evaluates telomerase activation and telomere maintenance in cancer cell lines using genomic and CRISPR data, finding correlations between TERT expression, telomere content, and epigenetic regulation.

Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis

The paper identifies sex-biased ZRSR2 mutations in BPDCN that impair pDC activation and apoptosis, linking X chromosome mutations to male-predominant leukemia.

Multiplexed single-cell profiling of post-perturbation transcriptional responses to define cancer vulnerabilities and therapeutic mechanism of action

The paper introduces MIX-Seq, a method for multiplexed single-cell transcriptional profiling of cancer cell responses to perturbations, revealing drug mechanisms and predicting cell viability.

WRN Helicase is a Synthetic Lethal Target in Microsatellite Unstable Cancers

The paper identifies WRN helicase as a synthetic lethal target in microsatellite unstable cancers through CRISPR/Cas9 and RNAi screens, showing its essentiality in MSI cell lines.

Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition

This study identifies SMARCB1 loss as critical for RMC survival and shows proteasome inhibition as a potential therapeutic strategy.